• Corpus ID: 14824018

Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).

@article{Merlos1997RupatadineAN,
  title={Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).},
  author={Manuel Merlos and Marta Giral and Dolors Balsa and Rosa Ferrando and Mireia Queralt and Anna Puigdemont and Juli{\'a}n Garc{\'i}a-Rafanell and Javier Forn},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={1997},
  volume={280 1},
  pages={
          114-21
        }
}
  • M. MerlosM. Giral J. Forn
  • Published 1997
  • Biology, Chemistry, Medicine
  • The Journal of pharmacology and experimental therapeutics
Rupatadine (UR-12592, 8-chloro-6, 11-dihydro-11-[1-[(5-methyl3-pyridinyl) methyl]-4-piperidinylidene]-5H-benzo[5,6]-cyclohepta[1,2b]pyridine ) is a novel compound that inhibits both platelet-activating factor (PAF) and histamine (H1) effects through its interaction with specific receptors (Ki(app) values against [3H]WEB-2086 binding to rabbit platelet membranes and [3H]-pyrilamine binding to guinea pig cerebellum membranes were 0.55 and 0.10 microM, respectively). Rupatadine competitively… 

Figures and Tables from this paper

Antihistamine Activities of Iminodiacetamide Derivatives

Abstract − A series of N,N'- substituted iminodiacetamide derivatives was synthesized and evaluated their inhib-itory effects on the histamine-induced smooth muscle contraction in guinea-pig ileum

Effects of rupatadine, a new dual antagonist of histamine and platelet‐activating factor receptors, on human cardiac Kv1.5 channels

The effects of rupatadine, a new dual antagonist of both histamine H1 and platelet‐activating factor receptors, were studied on human cloned hKv1.5 channels and it is suggested that the drug binds to an internal site and dramatically modifies the voltage‐dependence of channel opening.

Effects of Rupatadine on Platelet- Activating Factor-Induced Human Mast Cell Degranulation Compared With Desloratadine and Levocetirizine (The MASPAF Study).

This study shows that rupatadine and, to a lesser extent, levocetirizine, inhibit PAF-induced degranulation in both LAD2 and hLMCs, and supports the dual antihistamine and anti-PAF effect of rup atadine in allergic disorders.

Royal Jelly-derived Two Compounds, 10-hydroxy-2-decenoic acid and a Biotinylated Royalisin-related Peptide, Alleviate Anaphylactic Hypothermia In vivo

Results suggest that both 10-HDA and Biotin-RL-Y11 may exert an anti-anaphylactic effect targeting PAF, an important mediator of allergic reactions such as anaphylaxis.

Inhibitory effects of rupatadine on mast cell histamine release and skin wheal development induced by Ascaris suum in hypersensitive dogs

Rupatadine is effective in controlling inflammatory reactions in dog skin and the effect may be partly due to its modulation of mast cell degranulation, but not to its PAF‐antagonist properties.

Rupatadine: a novel second-generation antihistamine

Clinical trials have indicated that rupatadine is significantly more effective than placebo and equally effective as other antihistamines of the second generation, and side effects are mild and moderate, the most common ones were headache and somnolence.

Central and Peripheral Evaluation of Rupatadine, a New Antihistamine/Platelet-Activating Factor Antagonist, at Different Doses in Healthy Volunteers

RU presents a potent dose-dependent peripheral anti-H1 activity, displaying psychomotor impairment activity only at the highest dose (80 mg), while therapeutically relevant lower doses (10 and 20 mg) were similar to placebo.

In vitro inhibitory effect of rupatadine on histamine and TNF-α release from dispersed canine skin mast cells and the human mast cell line HMC-1

Rup atadine and loratadine showed similar inhibitory effect on histamine and TNF-α release, whereas SR-27417A only exhibited inhibitoryEffect against TNF -α.

Novel targets and regulatory ordeal by QT interval.

  • J. Ritter
  • Biology, Medicine
    British journal of clinical pharmacology
  • 2010
The PAF pathway (of biosynthesis, receptors, and downstream transduction events) is thus an attractive therapeutic target, but it is not yet clear whether inhibiting it will prove therapeutically advantageous in thrombotic or inflammatory diseases.

Rupatadine inhibits inflammatory mediator release from human laboratory of allergic diseases 2 cultured mast cells stimulated by platelet-activating factor.

...

References

SHOWING 1-10 OF 49 REFERENCES

Sch 37370: a potent, orally active, dual antagonist of platelet-activating factor and histamine.

Platelet-activating factor (PAF) and histamine are potent bronchospastic agents and possess additional properties such as induction of vasopermeability and activation of inflammatory cells that are

Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor.

In conclusion, WEB 2086 is a potent and specific PAF antagonist with triazolodiazepine structure but without sedative activity.

Pharmacological characterization of a receptor for platelet-activating factor on guinea pig peritoneal macrophages using [3H]apafant, a selective and competitive platelet-activating factor antagonist: evidence that the noncompetitive behavior of apafant in functional studies relates to slow kinetics

It is concluded that guinea pig peritoneal macrophages express receptors for PAF for which apafant has high affinity, and the biphasic competition curves obtained with C18-PAF in binding experiments and the effect of guanosine-5'-O-(3-thio)triphosphate are consistent with the hypothesis that these apafan-sensitive PAF receptors are coupled to guanine nucleotide-binding proteins.

In vitro and in vivo binding characteristics of a new long-acting histamine H1 antagonist, astemizole.

The most striking property of this drug is its extremely slow dissociation rate from H1 receptors when assayed in vitro using [3H]-pyrilamine, and here again the most striking receptor binding property was its very long duration.

Differential plasma duration of antiplatelet‐activating factor and antihistamine activities of oral Sch 37370 in humans

It is concluded that, in humans, oral Sch 37370 antagonizes both PAF and histamine with plasma antihistamine activity lasting longer than plasma anti‐PAF activity.

Effect of loratadine on human eosinophil function in vitro.

It is suggested that loratadine has a direct inhibitory effect on eosinophil activation and may be beneficial in the therapy of allergic disorders with its anti-allergic properties.

Use of cetirizine to investigate non-H1 effects of second-generation antihistamines.

Results suggest that cetirizine acts on eosinophil migration to inhibit the late reaction, and markedly reduced both the immediate wheal and flare induced by PAF and the delayed reaction at six hours.

Influence of plasma protein content and platelet number on the potency of PAF and its antagonist RP 59227 in rabbit platelet preparations

Only platelet aggregation studies carried out by using well‐defined experimental conditions afford an appropriate investigational approach to establish a potency rank order for PAF‐receptor antagonists, and dil.